Skip to main content
. 2013 Aug 12;8(8):e72021. doi: 10.1371/journal.pone.0072021

Figure 3. Serum bevacizumab levels as a function of treatment efficacy.

Figure 3

(▪) mean value for patients with side effects (n = 5); (▴)mean value for patients with residual angiogenesis (n = 4); (♦) mean value for patients responding favorably to treatment (n = 4).